Analysis of one-month treatment cost and medical insurance reimbursement of inavolisib

Inavolisib (Inavolisib) is an oral small molecule PI3Kα inhibitor, mainly used to treat PIK3CA gene mutation-positive breast cancer and some solid tumor patients. As a targeted therapy drug, inarisep can selectively inhibit the abnormally activated PI3K signaling pathway in tumor cells, thereby inhibiting tumor cell proliferation and delaying disease progression. Due to its strong targeting and clear efficacy, it has become an important treatment option for some patients with refractory breast cancer.

In the domestic market, Inalise is already on the market, but it has not yet been included in the medical insurance system. Common specifications include 3mg7tablets4plates and 9mg7tablets4plates. According to current market information, its monthly treatment cost is about 30,000 yuan, which is relatively expensive and is a high-cost targeted therapy drug. This means that patients need to bear greater financial pressure during long-term treatment. At the same time, when choosing to use it, they need to evaluate treatment options based on their own economic conditions and disease conditions.

In comparison, the price of the original drug Inariside in overseas markets is higher, with each box selling for more than 200,000 yuan (affected by exchange rate fluctuations). Currently, there are no generic versions available overseas, so patients will face greater cost pressure if they choose to purchase drugs overseas. The high price also limits its accessibility to a wide range of people, making domestic patients more dependent on domestic marketing channels when choosing targeted therapies.

In general, the cost of treatment with inaliside in China is relatively high and is not reimbursed by medical insurance. Patients need to bear all drug costs out of their own pocket. Although expensive, it has significant efficacy in specific PIK3CA gene mutation-positive patients and can provide precise targeted treatment options. In the future, if negotiations for inclusion in medical insurance are successful or domestic generic drugs are launched, treatment costs are expected to be reduced, allowing more patients to obtain affordable targeted treatment options while ensuring clinical efficacy and safety.

Reference link:https://www.drugs.com

xa0